IPP Bureau
Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
By IPP Bureau - August 11, 2022
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
AI to shape future outcomes in cardiovascular care, says GlobalData
By IPP Bureau - August 11, 2022
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%
By IPP Bureau - August 10, 2022
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director
By IPP Bureau - August 10, 2022
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust
By IPP Bureau - August 10, 2022
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
By IPP Bureau - August 10, 2022
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr
By IPP Bureau - August 10, 2022
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
By IPP Bureau - August 09, 2022
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
Briefs: Zydus Lifesciences and Kimia Biosciences
By IPP Bureau - August 09, 2022
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Lyka Labs swings back to profit in Q1FY23
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad
By IPP Bureau - August 09, 2022
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
JB Pharma records revenue growth of 30% in Q1 FY23
By IPP Bureau - August 09, 2022
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
By IPP Bureau - August 09, 2022
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
